
|Articles|June 11, 2015
- Precision Medicine
- Volume 2
- Issue 1
Clinical Validation and Utility of a Liquid Biopsy in NSCLC
Author(s)Veena Singh, MD
Veena Singh, MD, senior vice president and senior medical director, Biocept, Inc., discusses the clinical validation and utility of a liquid biopsy in non-small cell lung cancer (NSCLC) using circulating tumor cells (CTCs) and ctDNA to analyze EGFR, ALK and ROS status.
Veena Singh, MD, senior vice president and senior medical director, Biocept, Inc., discusses the clinical validation and utility of a liquid biopsy in non-small cell lung cancer (NSCLC) using circulating tumor cells (CTCs) and ctDNA to analyze EGFR, ALK and ROS status.
<<<
Articles in this issue
almost 11 years ago
Early Detection of Resistance in Lung Cancer Detected Through ctDNA in Urinealmost 11 years ago
Nivolumab and Future Biomarkers in NSCLCalmost 11 years ago
Screening Needed for Younger Breast Cancer Patients Based on Mutation Yieldalmost 11 years ago
Significance of the NCI Molecular Analysis for Therapy Choice Programalmost 11 years ago
Scoring System May Help Guide Therapy in Triple-Negative Breast Cancer































